Purpose: To assess the value of liver parenchyma enhancement tracking for liver multidetector computed tomography (CT) in patients with potential hypoattenuating liver metastases.
Materials and methods: Institutional review board approved this Health Insurance Portability and Accountability Act-compliant study. We reviewed the chest-abdomen-pelvis CTs of 120 consecutive patients scanned on 16-/64-row multidetector CT after receiving 52 g I in 50 seconds. Liver scanning started 65 seconds after injection-start in 59 patients, whereas in 61 patients, scanning started automatically when liver enhancement reached 50 Hounsfield units on low-dose continuous attenuation tracking. Enhancement of liver parenchyma, aorta, portal, and hepatic veins was measured. Two readers graded conspicuity and recorded attenuation of hypoattenuating lesions.
Results: We identified 663 metastases in 74 patients. Scan-delay range in the triggered group was 53 to 83 seconds. Compared with the fixed-delay group, in the triggered group, mean number of metastases per patient with metastases was larger, liver attenuation and enhancement were higher, and median metastasis conspicuity grade was higher (all P < 0.05).
Conclusions: Automatic scan triggering based on liver parenchyma enhancement tracking produces consistently higher liver parenchymal enhancement and increased metastasis conspicuity than fixed delay.